Literature DB >> 5286686

Synchronization and recruitment in acute leukemia.

B C Lampkin, T Nagao, A M Mauer.   

Abstract

The in vivo effects of several chemotherapeutic agents on the mitotic cycle of leukemic blasts in the bone marrow were evaluated by serial measurements of cells in mitosis and in deoxyribonucleic acid (DNA) synthesis as indicated by ability to incorporate tritiated thymidine or tritiated deoxyuridine. 28 studies were done in 23 children and 1 adult. The changes in the marrow after a single injection of L-asparaginase, hydrocortisone, cyclophosphamide, cytosine arabinoside, methotrexate, and an exchange transfusion (62% of the total blood volume) were evaluated. L-asparaginase and hydrocortisone were found to arrest the entry of cells into the S period. Cyclophosphamide appeared to inhibit DNA synthesis, arrest cells in mitosis, and inhibit the entry of cells into the S period. Cytosine arabinoside, and methotrexate inhibited DNA synthesis. During the period of time the cells were inhibited in the S phase by these two drugs, cells continued to enter the S period. Thus partial synchronization was achieved after these two drugs. An exchange transfusion had no consistent effect on the mitotic cycle, but partial synchronization in the S period was seen in one patient. To take advantage of the ability of cystosine arabinoside, to synchronize leukemic cells in the S phase, a second cycle-dependent drug was given at the time the leukemic blasts were synchronized. The second cycle-dependent drugs evaluated were vincristine, methotrexate, and cytosine arabinoside given by intravenous drip over a 12 hr period. Recruitment was found after cytosine arabinoside alone, and after prior synchronization with cytosine arabinoside and then the administration of either of these drugs. The results of these studies indicate that a greater therapeutic advantage can be achieved by a second cycle-dependent drug after synchronization than after the second drug alone.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5286686      PMCID: PMC292155          DOI: 10.1172/JCI106715

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  13 in total

1.  PROLIFERATION AND MATURATION DEFECT IN ACUTE LEUKAEMIA CELLS.

Authors:  F GAVOSTO; A PILERI; C BACHI; L PEGORARO
Journal:  Nature       Date:  1964-07-04       Impact factor: 49.962

2.  CHARACTERISTICS OF CELL PROLIFERATION IN A PATIENT WITH ACUTE LEUKAEMIA.

Authors:  A M MAUER
Journal:  Lancet       Date:  1964-09-26       Impact factor: 79.321

3.  The acute leukemias. Analysis of 322 cases and review of the literature.

Authors:  D R BOGGS; M M WINTROBE; G E CARTWRIGHT
Journal:  Medicine (Baltimore)       Date:  1962-09       Impact factor: 1.889

4.  Volumetric and microscopic pattern of bone marrow in normal infants and children. I. Volumetric pattern.

Authors:  P STURGEON
Journal:  Pediatrics       Date:  1951-04       Impact factor: 7.124

5.  Synchronization of the mitotic cycle in acute leukaemia.

Authors:  B C Lampkin; T Nagao; A M Mauer
Journal:  Nature       Date:  1969-06-28       Impact factor: 49.962

6.  Proliferative activity of leukaemic cells at various stages of acute leukaemia of childhood.

Authors:  M D Foadi; E H Cooper; R M Hardisty
Journal:  Br J Haematol       Date:  1968-09       Impact factor: 6.998

7.  Characteristics of cell proliferation in four patients with untreated acute leukemia.

Authors:  A M Mauer; V Fisher
Journal:  Blood       Date:  1966-09       Impact factor: 22.113

8.  Variation of proliferative activity in leukemic cell populations of patients with acute leukemia.

Authors:  E F Saunders; B C Lampkin; A M Mauer
Journal:  J Clin Invest       Date:  1967-08       Impact factor: 14.808

9.  Reentry of nondividing leukemic cells into a proliferative phase in acute childhood leukemia.

Authors:  E F Saunders; A M Mauer
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

10.  Drug effect in acute leukemia.

Authors:  B C Lampkin; T Nagao; A M Mauer
Journal:  J Clin Invest       Date:  1969-06       Impact factor: 14.808

View more
  12 in total

1.  Specific suppression of antibody rebound after extracorporeal immunoadsorption. I. Comparison of single versus combination chemotherapeutic agents.

Authors:  D S Terman; R Garcia-Rinaldi; B Dannemann; D Moore; C Crumb; A Tavel; R Poser
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

Review 2.  [Present state in synchronization therapy of malignant tumors and acute leukemias (author's transl)].

Authors:  H Sauer; W Wilmanns
Journal:  Klin Wochenschr       Date:  1976-03-01

3.  Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-beta-D-arabinofuranosyluracil.

Authors:  B Chandrasekaran; T E Kute; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Methotrexate induced apoptotic and necrotic chromatin changes in rat myeloid leukemia cells.

Authors:  Gyorgy Trencsenyi; Fruzsina Bako; Gabor Nagy; Pal Kertai; Gaspar Banfalvi
Journal:  Inflamm Res       Date:  2015-02-12       Impact factor: 4.575

5.  Mode of action of chemotherapy in vivo on human acute leukemia. I. Daunomycin.

Authors:  P A Stryckmans; J Manaster; F Lachapelle; M Socquet
Journal:  J Clin Invest       Date:  1973-01       Impact factor: 14.808

6.  [Partial synchronization of tumor cells in vivo with hydroxyurea (author's transl)].

Authors:  R Hartenstein; K Pfundmair; K Possinger
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977

7.  Therapy of solid Walker carcinosarcoma 256 with bleomycin after synchronization with hydroxyurea.

Authors:  M Volm; J Mattern; N Weber; K Wayss
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 8.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

9.  Cell kinetics after high dose cytosine arabinoside in patients with acute myelocytic leukemia.

Authors:  L P Colly; W G Peters; M W Arentsen-Honders; R Willemze
Journal:  Blut       Date:  1990-02

10.  [Pharmakokinetics of hydroxy-urea. Therapy of acute myeoblastic leukemias using synchronization and recruitment effects (author' transl)].

Authors:  H Sauer; R Pelka; W Wilmanns
Journal:  Klin Wochenschr       Date:  1976-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.